Mayumi Nakagawa
Concepts (204)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Papillomavirus Infections | 14 | 2019 | 157 | 5.420 |
Why?
| Human papillomavirus 16 | 11 | 2021 | 51 | 4.390 |
Why?
| Papillomavirus Vaccines | 7 | 2021 | 66 | 4.010 |
Why?
| Uterine Cervical Neoplasms | 8 | 2021 | 285 | 3.090 |
Why?
| Oncogene Proteins, Viral | 11 | 2011 | 59 | 2.980 |
Why?
| Papillomaviridae | 7 | 2019 | 106 | 2.830 |
Why?
| Repressor Proteins | 9 | 2011 | 170 | 2.480 |
Why?
| Epitopes, T-Lymphocyte | 7 | 2018 | 32 | 2.330 |
Why?
| Cancer Vaccines | 3 | 2021 | 102 | 1.910 |
Why?
| T-Lymphocytes | 6 | 2021 | 334 | 1.690 |
Why?
| Candida | 4 | 2018 | 61 | 1.640 |
Why?
| CD8-Positive T-Lymphocytes | 6 | 2018 | 111 | 1.620 |
Why?
| Cervix Uteri | 3 | 2021 | 54 | 1.060 |
Why?
| Cervical Intraepithelial Neoplasia | 2 | 2015 | 42 | 1.030 |
Why?
| Immunity, Cellular | 4 | 2013 | 85 | 0.890 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 80 | 0.870 |
Why?
| Langerhans Cells | 3 | 2018 | 11 | 0.860 |
Why?
| Epitopes | 2 | 2015 | 84 | 0.860 |
Why?
| Neoplasms | 2 | 2021 | 1158 | 0.830 |
Why?
| Viral Load | 2 | 2019 | 87 | 0.800 |
Why?
| Cell Cycle Checkpoints | 1 | 2019 | 34 | 0.780 |
Why?
| HLA Antigens | 4 | 2006 | 52 | 0.760 |
Why?
| Health Education | 1 | 2021 | 190 | 0.750 |
Why?
| CD4-Positive T-Lymphocytes | 3 | 2018 | 190 | 0.680 |
Why?
| Adult | 19 | 2021 | 14064 | 0.640 |
Why?
| Plasma Exchange | 2 | 2014 | 33 | 0.620 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 546 | 0.610 |
Why?
| Humans | 37 | 2021 | 51226 | 0.600 |
Why?
| Cross Protection | 1 | 2015 | 6 | 0.600 |
Why?
| T-Lymphocytes, Regulatory | 2 | 2016 | 86 | 0.600 |
Why?
| Colposcopy | 1 | 2015 | 19 | 0.580 |
Why?
| Interleukin-12 | 2 | 2018 | 35 | 0.580 |
Why?
| Adjuvants, Immunologic | 2 | 2018 | 64 | 0.570 |
Why?
| Immunity, Innate | 1 | 2015 | 108 | 0.550 |
Why?
| Female | 25 | 2021 | 28342 | 0.550 |
Why?
| Lectins, C-Type | 1 | 2013 | 30 | 0.540 |
Why?
| Interferon-gamma | 2 | 2012 | 196 | 0.540 |
Why?
| Health | 1 | 2013 | 29 | 0.540 |
Why?
| Papillomavirus E7 Proteins | 8 | 2018 | 35 | 0.540 |
Why?
| Patient Selection | 1 | 2015 | 293 | 0.500 |
Why?
| Afibrinogenemia | 1 | 2012 | 5 | 0.500 |
Why?
| Enzyme-Linked Immunospot Assay | 1 | 2012 | 2 | 0.490 |
Why?
| T-Lymphocytes, Cytotoxic | 4 | 2009 | 76 | 0.480 |
Why?
| Young Adult | 8 | 2021 | 4171 | 0.480 |
Why?
| Middle Aged | 13 | 2021 | 13329 | 0.460 |
Why?
| Plateletpheresis | 1 | 2010 | 8 | 0.440 |
Why?
| Warts | 1 | 2010 | 23 | 0.440 |
Why?
| Antigens, Fungal | 1 | 2010 | 30 | 0.440 |
Why?
| Blood Preservation | 1 | 2010 | 31 | 0.430 |
Why?
| Dermatitis | 1 | 2010 | 37 | 0.430 |
Why?
| Cell Proliferation | 5 | 2021 | 1120 | 0.420 |
Why?
| Blood Proteins | 1 | 2010 | 102 | 0.420 |
Why?
| Anaphylaxis | 1 | 2010 | 70 | 0.410 |
Why?
| Telemedicine | 1 | 2015 | 398 | 0.390 |
Why?
| Antigens, Viral | 2 | 2009 | 54 | 0.380 |
Why?
| Human papillomavirus 18 | 1 | 2008 | 10 | 0.370 |
Why?
| Cells, Cultured | 5 | 2021 | 1828 | 0.370 |
Why?
| Immunotherapy | 1 | 2010 | 243 | 0.370 |
Why?
| Blood Platelets | 1 | 2010 | 302 | 0.350 |
Why?
| Vaccinia virus | 1 | 2007 | 7 | 0.340 |
Why?
| Host-Pathogen Interactions | 2 | 2021 | 151 | 0.340 |
Why?
| Dendritic Cells | 1 | 2008 | 148 | 0.340 |
Why?
| Immunophenotyping | 1 | 2007 | 128 | 0.330 |
Why?
| Immunoenzyme Techniques | 1 | 2007 | 173 | 0.330 |
Why?
| Isoantibodies | 1 | 2004 | 34 | 0.290 |
Why?
| Neoplasm Grading | 2 | 2021 | 132 | 0.280 |
Why?
| Lead | 1 | 2004 | 34 | 0.280 |
Why?
| Cell Line, Tumor | 5 | 2021 | 1476 | 0.280 |
Why?
| Infant, Very Low Birth Weight | 1 | 2004 | 53 | 0.280 |
Why?
| Neutropenia | 1 | 2004 | 116 | 0.280 |
Why?
| DNA, Viral | 3 | 2011 | 151 | 0.260 |
Why?
| Blood Transfusion | 1 | 2004 | 126 | 0.260 |
Why?
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 194 | 0.250 |
Why?
| Aged | 8 | 2021 | 10169 | 0.250 |
Why?
| Capsid Proteins | 1 | 2002 | 24 | 0.250 |
Why?
| Early Detection of Cancer | 2 | 2021 | 130 | 0.240 |
Why?
| Antibody Formation | 1 | 2002 | 65 | 0.240 |
Why?
| Adolescent | 5 | 2021 | 6735 | 0.240 |
Why?
| Genes, T-Cell Receptor | 1 | 2021 | 4 | 0.240 |
Why?
| Clone Cells | 3 | 2007 | 87 | 0.240 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 2021 | 30 | 0.230 |
Why?
| Remission Induction | 1 | 2021 | 218 | 0.220 |
Why?
| Left-Right Determination Factors | 1 | 2020 | 1 | 0.220 |
Why?
| Cystadenocarcinoma, Serous | 1 | 2021 | 70 | 0.220 |
Why?
| Nodal Protein | 1 | 2020 | 3 | 0.220 |
Why?
| Vaginal Smears | 2 | 2011 | 31 | 0.220 |
Why?
| Videotape Recording | 1 | 2021 | 35 | 0.220 |
Why?
| Cytokines | 2 | 2016 | 683 | 0.220 |
Why?
| Pilot Projects | 2 | 2021 | 775 | 0.220 |
Why?
| Treatment Outcome | 3 | 2021 | 5480 | 0.220 |
Why?
| Lymphocyte Activation | 1 | 2021 | 213 | 0.220 |
Why?
| Amino Acid Sequence | 3 | 2008 | 761 | 0.210 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 309 | 0.200 |
Why?
| Metagenome | 1 | 2019 | 49 | 0.200 |
Why?
| Feasibility Studies | 1 | 2021 | 399 | 0.200 |
Why?
| Glioblastoma | 1 | 2020 | 81 | 0.200 |
Why?
| Health Behavior | 1 | 2021 | 270 | 0.180 |
Why?
| Up-Regulation | 1 | 2020 | 528 | 0.180 |
Why?
| Dose-Response Relationship, Drug | 2 | 2016 | 1556 | 0.180 |
Why?
| Multiple Myeloma | 1 | 2012 | 2714 | 0.180 |
Why?
| HLA-B Antigens | 2 | 2008 | 7 | 0.180 |
Why?
| Leukocytes, Mononuclear | 2 | 2016 | 136 | 0.170 |
Why?
| DNA | 1 | 2021 | 565 | 0.170 |
Why?
| Brain Neoplasms | 1 | 2020 | 249 | 0.170 |
Why?
| Bacteria | 1 | 2019 | 229 | 0.170 |
Why?
| Ovarian Neoplasms | 1 | 2021 | 441 | 0.160 |
Why?
| Age Factors | 1 | 2021 | 1246 | 0.160 |
Why?
| Histocompatibility Antigens Class II | 2 | 2008 | 42 | 0.160 |
Why?
| Cell Line | 2 | 2012 | 1215 | 0.160 |
Why?
| Vaccines, Subunit | 1 | 2016 | 21 | 0.160 |
Why?
| Male | 8 | 2021 | 27647 | 0.160 |
Why?
| Head and Neck Neoplasms | 1 | 2019 | 310 | 0.150 |
Why?
| Adaptive Immunity | 1 | 2015 | 38 | 0.150 |
Why?
| Leukocyte Count | 2 | 2004 | 82 | 0.140 |
Why?
| Chromatography, Liquid | 1 | 2016 | 240 | 0.140 |
Why?
| Molecular Sequence Data | 2 | 2008 | 971 | 0.140 |
Why?
| Tandem Mass Spectrometry | 1 | 2016 | 241 | 0.140 |
Why?
| Factor VIII | 1 | 2014 | 23 | 0.140 |
Why?
| Vaccination | 1 | 2016 | 189 | 0.140 |
Why?
| Purpura, Thrombotic Thrombocytopenic | 1 | 2014 | 18 | 0.140 |
Why?
| ADAM Proteins | 1 | 2014 | 26 | 0.140 |
Why?
| Antigens, CD1 | 1 | 2013 | 8 | 0.140 |
Why?
| Peptides | 2 | 2006 | 280 | 0.140 |
Why?
| Mannose-Binding Lectins | 1 | 2013 | 10 | 0.140 |
Why?
| Receptors, Pattern Recognition | 1 | 2013 | 5 | 0.140 |
Why?
| Proteome | 1 | 2016 | 168 | 0.140 |
Why?
| Indicators and Reagents | 1 | 2013 | 58 | 0.140 |
Why?
| Intracellular Space | 1 | 2013 | 30 | 0.140 |
Why?
| Skin Tests | 1 | 2013 | 57 | 0.140 |
Why?
| Time Factors | 1 | 2021 | 3392 | 0.130 |
Why?
| Cadherins | 1 | 2013 | 78 | 0.130 |
Why?
| Proteomics | 1 | 2016 | 314 | 0.130 |
Why?
| Communication | 1 | 2015 | 260 | 0.120 |
Why?
| Research Design | 1 | 2015 | 348 | 0.120 |
Why?
| Rural Health Services | 1 | 2015 | 200 | 0.120 |
Why?
| Socioeconomic Factors | 1 | 2015 | 629 | 0.120 |
Why?
| Antigens, CD | 1 | 2013 | 264 | 0.120 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 699 | 0.120 |
Why?
| Longitudinal Studies | 2 | 2005 | 684 | 0.110 |
Why?
| Injections, Intralesional | 1 | 2010 | 40 | 0.110 |
Why?
| Isotonic Solutions | 1 | 2010 | 23 | 0.110 |
Why?
| Platelet Transfusion | 1 | 2010 | 34 | 0.110 |
Why?
| P-Selectin | 1 | 2010 | 45 | 0.110 |
Why?
| Sodium Chloride | 1 | 2010 | 62 | 0.110 |
Why?
| Platelet Aggregation | 1 | 2010 | 90 | 0.110 |
Why?
| Platelet Activation | 1 | 2010 | 65 | 0.100 |
Why?
| Hypersensitivity | 1 | 2010 | 65 | 0.100 |
Why?
| HLA-A Antigens | 1 | 2008 | 14 | 0.090 |
Why?
| Antigen Presentation | 1 | 2008 | 25 | 0.090 |
Why?
| Immunologic Memory | 1 | 2008 | 31 | 0.090 |
Why?
| Histocompatibility Antigens Class I | 1 | 2008 | 44 | 0.090 |
Why?
| Polymerase Chain Reaction | 1 | 2010 | 532 | 0.090 |
Why?
| DNA, Recombinant | 1 | 2007 | 18 | 0.090 |
Why?
| African Americans | 1 | 2013 | 711 | 0.090 |
Why?
| Genes, MHC Class I | 1 | 2006 | 11 | 0.080 |
Why?
| Signal Transduction | 2 | 2020 | 1812 | 0.080 |
Why?
| Binding, Competitive | 1 | 2006 | 133 | 0.080 |
Why?
| Arkansas | 1 | 2013 | 2146 | 0.080 |
Why?
| Retrospective Studies | 2 | 2010 | 5788 | 0.080 |
Why?
| Animals | 2 | 2019 | 14412 | 0.080 |
Why?
| Calgranulin B | 1 | 2005 | 7 | 0.070 |
Why?
| Calgranulin A | 1 | 2005 | 9 | 0.070 |
Why?
| Neoplasm Staging | 1 | 2008 | 799 | 0.070 |
Why?
| Immunomagnetic Separation | 1 | 2004 | 10 | 0.070 |
Why?
| Epitope Mapping | 1 | 2004 | 13 | 0.070 |
Why?
| Risk Factors | 1 | 2013 | 3924 | 0.070 |
Why?
| Phosphorylation | 2 | 2020 | 624 | 0.060 |
Why?
| Sensitivity and Specificity | 1 | 2005 | 960 | 0.060 |
Why?
| Tumor Virus Infections | 1 | 2002 | 44 | 0.060 |
Why?
| Antibodies, Viral | 1 | 2002 | 87 | 0.060 |
Why?
| Lactobacillus | 1 | 2021 | 8 | 0.060 |
Why?
| SOX Transcription Factors | 1 | 2021 | 4 | 0.060 |
Why?
| Immunoglobulin G | 1 | 2002 | 214 | 0.060 |
Why?
| Cytodiagnosis | 1 | 2021 | 43 | 0.060 |
Why?
| Neuroendocrine Cells | 1 | 2021 | 11 | 0.060 |
Why?
| Biological Specimen Banks | 1 | 2021 | 25 | 0.060 |
Why?
| Cobalt | 1 | 2020 | 15 | 0.060 |
Why?
| Cytoplasm | 1 | 2021 | 111 | 0.060 |
Why?
| Vulnerable Populations | 1 | 2020 | 40 | 0.050 |
Why?
| Cell Hypoxia | 1 | 2020 | 92 | 0.050 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2020 | 54 | 0.050 |
Why?
| Neoplastic Stem Cells | 1 | 2021 | 102 | 0.050 |
Why?
| Recurrence | 1 | 2002 | 690 | 0.050 |
Why?
| Community Health Workers | 1 | 2020 | 52 | 0.050 |
Why?
| Cohort Studies | 1 | 2004 | 1485 | 0.050 |
Why?
| Cell Movement | 1 | 2021 | 303 | 0.050 |
Why?
| Multivariate Analysis | 1 | 2021 | 688 | 0.050 |
Why?
| Sequence Analysis, DNA | 1 | 2019 | 259 | 0.050 |
Why?
| Cell Survival | 1 | 2020 | 687 | 0.050 |
Why?
| Immunity, Humoral | 1 | 2018 | 22 | 0.050 |
Why?
| Cell Differentiation | 1 | 2021 | 749 | 0.040 |
Why?
| Phenotype | 1 | 2021 | 814 | 0.040 |
Why?
| Models, Biological | 1 | 2021 | 846 | 0.040 |
Why?
| Infant, Newborn | 1 | 2004 | 2740 | 0.040 |
Why?
| Mass Screening | 1 | 2020 | 370 | 0.040 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 880 | 0.040 |
Why?
| Prognosis | 1 | 2021 | 2077 | 0.040 |
Why?
| Autoantibodies | 1 | 2014 | 122 | 0.030 |
Why?
| Immunosuppressive Agents | 1 | 2014 | 252 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2014 | 703 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2018 | 2029 | 0.030 |
Why?
| Mice | 1 | 2018 | 6254 | 0.020 |
Why?
| Casein Kinase II | 1 | 2005 | 11 | 0.020 |
Why?
| Cell Division | 1 | 2005 | 367 | 0.020 |
Why?
|
|
Nakagawa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|